| Names | |
|---|---|
| IUPAC name (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
| Other names Antibiotic E 1077 | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C20H25FN8O6S2 | |
| Molar mass | 556.59 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Cefluprenam is a fourth generation cephalosporin. [1] It was patented in 2008 by now defunct Cubist Pharmaceuticals. [2] A 1997 clinical trial illustrated that Cefluprenam is highly effective against bacterial pneumonia. [3]